First therapy to treat transplant patients with post-transplant lymphoproliferative disease approved for marketing authorisation by the European Medicines Agency (EMA), October 14, 2022

On October 14, 2022, the European Medicines Agency (EMA) announced that it has recommended a marketing authorisation in the EU for Ebvallo (tabelecleucel), a medicine used to treat adults and children from 2 years of age who, after receiving an organ, or a bone marrow-transplantation, develop a blood cancer called Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). PTLD is rare, and Ebvallo was designated as an ‘orphan medicine’ (a medicine used in rare diseases) on 21 March 2016. The applicant for Ebvallo is Atara Biotherapeutics Ireland Limited.

Read more on the EMA website at this link

Photo credit: Unsplash

Scroll to Top